Walleye Capital
BCLI

Walleye Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Walleye Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-709
Closed -$35 – 2099
2021
Q3 		$35 Buy
+709
New +$37.3K ﹤0.01% 1433
2021
Q1 		– Sell
-1,078
Closed -$73 – 1177
2020
Q4 		$73 Buy
+1,078
New +$147K ﹤0.01% 841

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's BCLI Position: Q4 2021 in Review

Walleye Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2021, closing a stake of 709 shares — an estimated $35 sold.

Walleye Capital first reported a position in BCLI in Q4 2020 and held it in 2 quarters. The position peaked at $73 in Q4 2020. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2021.

  • Walleye Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2021 after selling out during the quarter.
  • Walleye Capital sold 709 BRAINSTORM CELL THERAPUTC shares in Q4 2021, an estimated $35.
  • Walleye Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 2 quarters.
  • Walleye Capital's BRAINSTORM CELL THERAPUTC position peaked at $73 in Q4 2020.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.